Introduction:

Invasive meningococcal disease (IMD) is a severe acute bacterial infection, and in the vast majority of cases is caused by five serogroups of Neisseriameningitidis (A, B, C, W, Y). The burden of disease and high mortality rates highlight the need for prevention through effective and safe active immunization.

Objective:

Describe the efficacy and safety of the quadrivalent meningococcal vaccine.

Methods:

This is a systematic review study. The proposals to improve the publication of PRISMAScR systematic reviews were followed. All articles available in English, published in peer-reviewed academic journals, and published between 2017 and 2022 were included. Articles describing the efficacy and safety of vaccines other than quadrivalent meningococcal vaccines were excluded.

Results:

After content analysis of the 8 included articles, four ACWY meningococcal vaccine themes were identified: infants and toddlers, children 2-10 years, adolescents, and adults, all ages. Regarding safety, regardless of age range, we highlight injection site pain as one of the most common adverse effect registry reports. In relation to efficacy, the articles analyzed focus on the persistence of antibodies over time in relation to doses/age.

Conclusions:

There is a clear need to develop effective and safe standardized tools in the meningococcal vaccine, since at the international level there are different vaccine strategies, presentations and immune responses.

        · resumen en Español     · texto en Español     · Español ( pdf )